Literature DB >> 31138085

Serum NfL (Neurofilament Light Chain) Levels and Incident Stroke in Adults With Diabetes Mellitus.

Frederick K Korley1, Jason Goldstick2, Mitra Mastali3, Jennifer E Van Eyk3, William Barsan1, William J Meurer1, Jeremy Sussman4, Hayley Falk1, Deborah Levine5,6.   

Abstract

Background and Purpose- Effective stroke prevention depends on accurate stroke risk prediction. We determined the discriminative ability of NfL (neurofilament light chain) levels for distinguishing between adults with diabetes mellitus who develop incident stroke and those who remain stroke free during a 7-year follow-up period. Methods- We performed a case-control study of participants selected from the previously completed ACCORD trial (Action to Control Cardiovascular Risk in Diabetes). Cases were all ACCORD subjects who were stroke free at enrollment and developed incident stroke during follow-up (n=113). Control subjects (n=250) were randomly selected ACCORD subjects who had no stroke events either before or after randomization. NfL was measured in baseline samples using Single Molecule Array technology (Quanterix). Results- Baseline NfL levels were higher in stroke subjects, compared to controls, after adjusting for age, race, blood pressure, weight, and the Framingham Stroke Risk Score. Relative to the subjects in the lowest quintile of NfL levels, the hazard ratios of incident stroke for subjects in the second to fifth quintiles were 3.91 (1.45-10.53), 4.05 (1.52-10.79), 5.63 (2.16-14.66), and 9.75 (3.84-27.71), respectively, after adjusting for race and Framingham Stroke Risk Score. Incorporating NfL levels into a predictive score that already included race and Framingham Stroke Risk Score increased the score's C statistic from 0.71 (95% CI, 0.66-0.77) to 0.78 (95% CI, 0.73-0.83), P<0.001. Older age, nonwhite race, higher systolic blood pressure, glomerular filtration rate <60, and higher hemoglobin A1C were independent predictors of serum NfL in this cohort but diastolic blood pressure, durations of hypertension or diabetes mellitus, and lipid levels were not. In total, cardiovascular disease risk factors explained 19.2% of the variability in baseline NfL levels. Conclusions- Serum NfL levels predict incident stroke and add considerably to the discriminatory power of the Framingham Stroke Risk Score in a cohort of middle-aged and older adults with diabetes mellitus.

Entities:  

Keywords:  adult; diabetes mellitus; primary prevention; risk factors; stroke

Mesh:

Substances:

Year:  2019        PMID: 31138085      PMCID: PMC6591022          DOI: 10.1161/STROKEAHA.119.024941

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  21 in total

1.  Combining diagnostic test results to increase accuracy.

Authors:  M S Pepe; M L Thompson
Journal:  Biostatistics       Date:  2000-06       Impact factor: 5.899

Review 2.  Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood.

Authors:  Henrik Zetterberg; Douglas H Smith; Kaj Blennow
Journal:  Nat Rev Neurol       Date:  2013-02-12       Impact factor: 42.937

3.  Seeking the "holy grail" of biomarkers to improve stroke risk prediction of clinical scores.

Authors:  Stephen R Williams; Svetlana Lorenzano
Journal:  Neurology       Date:  2016-08-24       Impact factor: 9.910

4.  Silent MRI infarcts and the risk of future stroke: the cardiovascular health study.

Authors:  C Bernick; L Kuller; C Dulberg; W T Longstreth; T Manolio; N Beauchamp; T Price
Journal:  Neurology       Date:  2001-10-09       Impact factor: 9.910

5.  Serum neurofilament light chain in patients with acute cerebrovascular events.

Authors:  G M De Marchis; M Katan; C Barro; J Fladt; C Traenka; D J Seiffge; L Hert; H Gensicke; G Disanto; R Sutter; N Peters; H Sarikaya; B Goeggel-Simonetti; M El-Koussy; S Engelter; P A Lyrer; M Christ-Crain; M Arnold; J Kuhle; L H Bonati
Journal:  Eur J Neurol       Date:  2018-01-24       Impact factor: 6.089

Review 6.  Silent brain infarction--a review of recent observations.

Authors:  Katalin Réka Kovács; Dániel Czuriga; Dániel Bereczki; Natan M Bornstein; László Csiba
Journal:  Int J Stroke       Date:  2012-08-01       Impact factor: 5.266

7.  Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: a prospective cohort study.

Authors:  Hirokazu Bokura; Shotai Kobayashi; Shuhei Yamaguchi; Kenichi Iijima; Atsushi Nagai; Genya Toyoda; Hiroaki Oguro; Kazuo Takahashi
Journal:  J Stroke Cerebrovasc Dis       Date:  2006 Mar-Apr       Impact factor: 2.136

Review 8.  Silent Brain Infarction and Risk of Future Stroke: A Systematic Review and Meta-Analysis.

Authors:  Ajay Gupta; Ashley E Giambrone; Gino Gialdini; Caitlin Finn; Diana Delgado; Jose Gutierrez; Clinton Wright; Alexa S Beiser; Sudha Seshadri; Ankur Pandya; Hooman Kamel
Journal:  Stroke       Date:  2016-03       Impact factor: 7.914

9.  Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study.

Authors:  Stéphanie Debette; Alexa Beiser; Charles DeCarli; Rhoda Au; Jayandra J Himali; Margaret Kelly-Hayes; Jose R Romero; Carlos S Kase; Philip A Wolf; Sudha Seshadri
Journal:  Stroke       Date:  2010-02-18       Impact factor: 7.914

10.  Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.

Authors:  Ching-Hua Lu; Corrie Macdonald-Wallis; Elizabeth Gray; Neil Pearce; Axel Petzold; Niklas Norgren; Gavin Giovannoni; Pietro Fratta; Katie Sidle; Mark Fish; Richard Orrell; Robin Howard; Kevin Talbot; Linda Greensmith; Jens Kuhle; Martin R Turner; Andrea Malaspina
Journal:  Neurology       Date:  2015-05-01       Impact factor: 9.910

View more
  21 in total

1.  Contributors to Serum NfL Levels in People without Neurologic Disease.

Authors:  Kathryn C Fitzgerald; Elias S Sotirchos; Matthew D Smith; Hannah-Noelle Lord; Anna DuVal; Ellen M Mowry; Peter A Calabresi
Journal:  Ann Neurol       Date:  2022-07-13       Impact factor: 11.274

Review 2.  Promising Blood Biomarkers for Clinical Use in Alzheimer's Disease: A Focused Update.

Authors:  Sun Ah Park; Yu Jung Jang; Min Kyoung Kim; Sun Min Lee; So Young Moon
Journal:  J Clin Neurol       Date:  2022-07       Impact factor: 2.566

3.  Association of Plasma Neurofilament Light Chain With Glycaemic Control and Insulin Resistance in Middle-Aged Adults.

Authors:  Rohith N Thota; Pratishtha Chatterjee; Steve Pedrini; Eugene Hone; Jessica J A Ferguson; Manohar L Garg; Ralph N Martins
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-20       Impact factor: 6.055

4.  Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Nicholas M Pajewski; Fanny M Elahi; Manjula Kurella Tamura; Jason D Hinman; Ilya M Nasrallah; Joachim H Ix; Lindsay M Miller; Lenore J Launer; Clinton B Wright; Mark A Supiano; Alan J Lerner; Tiffany L Sudduth; Anthony A Killeen; Alfred K Cheung; David M Reboussin; Donna M Wilcock; Jeff D Williamson
Journal:  Alzheimers Dement       Date:  2021-11-17       Impact factor: 16.655

5.  Serum Neurofilament Light Predicts Severity and Prognosis in Patients with Ischemic Stroke.

Authors:  Peng Wang; Jia Fan; Ling Yuan; Yi Nan; Shanji Nan
Journal:  Neurotox Res       Date:  2020-01-02       Impact factor: 3.911

6.  A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation study.

Authors:  E A J Willemse; P Scheltens; C E Teunissen; E G B Vijverberg
Journal:  Alzheimers Res Ther       Date:  2021-05-18       Impact factor: 6.982

7.  Serum neurofilament measurement improves clinical risk scores for outcome prediction after cardiac arrest: results of a prospective study.

Authors:  Adrian Quinto; Maja Ramin-Wright; Sabina Hunziker; Christoph Becker; Katharina Beck; Alessia Vincent; Kai Tisljar; Giulio Disanto; Pascal Benkert; David Leppert; Hans Pargger; Stephan Marsch; Nils Peters; Jens Kuhle
Journal:  Crit Care       Date:  2021-01-20       Impact factor: 9.097

Review 8.  Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation.

Authors:  Simon Thebault; Ronald A Booth; Carolina A Rush; Heather MacLean; Mark S Freedman
Journal:  Front Neurosci       Date:  2021-03-25       Impact factor: 4.677

9.  Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis.

Authors:  Jasmini Alagaratnam; Sophia von Widekind; Davide De Francesco; Jonathan Underwood; Paul Edison; Alan Winston; Henrik Zetterberg; Sarah Fidler
Journal:  BMJ Neurol Open       Date:  2021-06-16

Review 10.  Blood neurofilament light: a critical review of its application to neurologic disease.

Authors:  Christian Barro; Tanuja Chitnis; Howard L Weiner
Journal:  Ann Clin Transl Neurol       Date:  2020-11-04       Impact factor: 5.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.